PeptideStack
5.2kquestions
20kanswers
220users

What is the reported incidence of hair thinning on mazdutide in FLOW?

Asked 7 Sept 2025Modified 7 months agoViewed 16k times
This question was closed as primarily opinion-based.Closed 27 Sept 2025. Answers already posted are preserved; new answers are not accepted. Questions here need a factual basis on which they can be answered.
30

Setup, so nobody has to ask: hair thinning · mazdutide · FLOW.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What would I need in addition before this supported a decision?

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

346 questions
shareeditfollowflag
LQ
askedlipid_panel_q44k1387 Sept 2025
6Does this hold at lower concentrations, or does adsorption dominate? – rania_haddad 6 months ago
5Worth flagging that this changed in 2025, so older answers on the site are out of date. – vialroom 4 months ago
add a comment

3 Answers

Accepted answer first, then by votes
29

Accepted answer

The relevant detail is that timing is the most useful diagnostic feature here and it is the one most often omitted from the question.

Constipation outlasts the nausea because it has two causes and only one of them resolves. Gastric emptying accommodates over weeks; total intake, and therefore stool volume and the osmotic load reaching the colon, does not recover until intake does. This is why fibre alone can make it worse — you add bulk to a system that is short of water and short of motility.

Gastrointestinal adverse events, indicative pooled rates

EventActive armPlacebo armTiming
Nausea40–45 %15–20 %Peaks 1–2 wk after each step
Vomiting15–25 %5–8 %Follows nausea
Diarrhoea20–30 %10–15 %Early, variable
Constipation20–25 %8–12 %Later onset, persistent
Discontinuation for GI events4–7 %1–2 %Mostly during escalation

Ranges span agents and doses; read the specific prescribing information for a specific figure.

Specifically, fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.

SURMOUNT-1 reported gastrointestinal events as the most frequent adverse events, mostly mild to moderate and mostly during escalation, with discontinuation for adverse events in the single digits per cent[1].

I would flag that attributing a symptom to a drug is a hypothesis, and the base rate of these symptoms in the general population is high enough that the hypothesis is often wrong.

A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.

edited 12 Jan 2026 by rania_haddad — clarified the distinction between purity and content

shareimprove this answerflag
RH
answered · acceptedrania_haddad17k2821 Dec 2025
6Is there a reason to prefer the second method over the first, other than cost? – coldbox9 5 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
14

The mechanism explains the pattern. Delayed gastric emptying plus central appetite suppression produces early satiety, and early satiety plus a slowed transit produces exactly the symptom cluster people report.

Injection-site reactions are more often diluent-related than peptide-related. Benzyl alcohol sensitivity is uncommon but real, and it presents as a consistent local reaction at every site with a preserved diluent and no reaction with an unpreserved one — which is a straightforward thing to establish. Injection depth is the other common cause: intradermal placement stings and welts, subcutaneous placement usually does not.

The part that matters: the telogen effluvium timing signature is the diagnostic feature: hair enters the shedding phase two to four months after the insult, so shedding that starts at month three of rapid loss and peaks around month four to five is the expected pattern. Shedding that starts in week two is not telogen effluvium and warrants a different question. In either case the follicle is not destroyed and regrowth is the rule.

The limitation of the timing heuristic is that it works well for common events and poorly for rare ones, which are precisely the ones that matter most.

If the timing does not fit the escalation, look for another explanation before settling on the drug.

shareimprove this answerflag
TR
answeredtadhg_o_riordan14k281 Jan 2026
7Small correction: the units in the third paragraph should be micrograms, not milligrams. – tare_weight 5 months ago
8Do you have a reference for the last claim? Not disputing it, just want to read it. – RP_C18 7 months ago
add a comment
-2

The distinction worth making early is between a tolerability problem, which is unpleasant and self-limiting, and a clinical problem, which is neither. They present differently and the thresholds for each are worth writing down before you need them.

The gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.

Vomiting matters mostly through its consequences. Loss of gastric fluid depletes sodium, chloride and potassium, and hypokalaemia presents as exactly the fatigue and cramping people attribute to the drug. Persistent vomiting also makes a renal panel uninterpretable, because a pre-renal picture looks like renal impairment.

The prescribing information for each agent lists adverse reaction frequencies against placebo in a table, and reading that table is more informative than reading a hundred anecdotes, because it has a denominator.

One qualification — reported incidence in a monitored trial population is a lower bound on what happens in an unmonitored one, because trial participants were escalated to protocol and supported through it.

Fix the fixable causes first — fluid, electrolytes, sleep, intake — before concluding that the compound is responsible.

shareimprove this answerflag
VI
answeredvialroom87k14810 Dec 2025
3This is the first explanation of that which has actually made sense to me. – ines_brandt 3 months ago
2Note that the label instructions differ between agents on precisely this point. – charge_state_3 2 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.